PATENT CLAIM ANALYSIS

Application Number: 15894025
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "215000"]

Abstract:
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Claim (Index 33):
A pharmaceutical composition comprising a compound  claim 18 , or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, together with one or more pharmaceutically acceptable excipients.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 88.0
- Lexical Diversity: 1.56364
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15513125', '16070936', '16060299', '15738900', '16080506']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8139033432953783
- 35 USC 102 Novelty (BERT): 0.6478115747846904
- Combined Prediction Score: 0.7972941664443095
- Mean Citation Score: 564.0303700000002
- Max Citation Score: 695.69135
- Similarity Product: 561.16535847978

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test